Compare · LLY vs PHAT
LLY vs PHAT
Side-by-side comparison of Eli Lilly and Company (LLY) and Phathom Pharmaceuticals Inc. (PHAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PHAT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.07T, about 1318.8x PHAT ($807.9M).
- Over the past year, LLY is up 46.4% and PHAT is up 14.6% - LLY leads by 31.9 points.
- LLY has been more active in the news (16 items in the past 4 weeks vs 11 for PHAT).
- LLY has more recent analyst coverage (25 ratings vs 11 for PHAT).
- Company
- Eli Lilly and Company
- Phathom Pharmaceuticals Inc.
- Price
- $1132.80+0.65%
- $10.14+3.05%
- Market cap
- $1.07T
- $807.9M
- 1M return
- +14.77%
- -19.97%
- 1Y return
- +46.44%
- +14.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 16
- 11
- Recent ratings
- 25
- 11
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Latest LLY
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
Latest PHAT
- Director Parikh Asit received a gift of 28,000 shares and gifted 28,000 shares, decreasing direct ownership by 54% to 24,122 units (SEC Form 4)
- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Director Parikh Asit was granted 24,122 shares and exercised 17,500 shares at a strike of $4.95, increasing direct ownership by 396% to 52,122 units (SEC Form 4)
- Director Fields Heidi was granted 24,122 shares, increasing direct ownership by 80% to 54,122 units (SEC Form 4)
- Director Topper James N was granted 24,122 shares, increasing direct ownership by 57% to 66,718 units (SEC Form 4)
- Director Stenhouse Mark was granted 24,122 shares, increasing direct ownership by 80% to 54,122 units (SEC Form 4)
- Director Schroeder Theodore R was granted 24,122 shares, increasing direct ownership by 115% to 45,122 units (SEC Form 4)
- Director Cola Michael F was granted 24,122 shares, increasing direct ownership by 61% to 63,920 units (SEC Form 4)
- Director Karbe Frank was granted 24,122 shares, increasing direct ownership by 36% to 91,622 units (SEC Form 4)
- SEC Form 8-K filed by Phathom Pharmaceuticals Inc.